NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Collegium Pharmaceutical Inc is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.
Collegium Pharmaceutical develops and commercializes prescription medications for attention deficit hyperactivity disorder and pain management. The company's product portfolio includes Jornay PM for ADHD, Belbuca and Xtampza ER for severe pain, the Nucynta Products for moderate to severe pain, and Symproic for opioid-induced constipation, all marketed in the United States.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Collegium Pharmaceutical Inc stock.
Undervalued: intrinsic value $93.47 per share, market price $23.01, margin of safety 75.4% (as of 2026-10-19).
Discounting its cash flows at 7.2% (average of 3 methods) values the shares at $93.47; the price of $23.01 is 75% below that value, and 83% of that value comes from beyond year five.
Leak Score: 79/100 on 12 of 12 signals (Clear Leak).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
COLL is undervalued (as of the 2026-10-19 close). Discounting its cash flows at 7.2% (average of 3 methods) values the shares at $93.47; the price of $23.01 is 75% below that value, and 83% of that value comes from beyond year five.
$93.47 per share (as of the 2026-10-19 close), against a market price of $23.01. That is a margin of safety of 75.4%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
79 out of 100, which we rate "Clear Leak", on 12 of 12 value investing signals.